Literature DB >> 11981734

Rhodococcus equi: an emerging pathogen.

David M Weinstock1, Arthur E Brown.   

Abstract

More than 100 cases of Rhodococcus equi infection have been reported since the first description of human disease caused by this organism. The vast majority of patients infected with R. equi are immunocompromised, and two-thirds have human immunodeficiency virus infection. The clinical manifestations of R. equi infection are diverse, although 80% of patients have some pulmonary involvement. The organism is easily cultured from specimens of infected tissue or body fluid, but it may be misdiagnosed as a contaminant. Treatment is often prolonged, and relapses at distant sites are common. This article summarizes the history, diagnosis, clinical features, and treatment of infection with this emerging pathogen.

Entities:  

Mesh:

Year:  2002        PMID: 11981734     DOI: 10.1086/340259

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  67 in total

1.  Internally controlled real-time PCR method for quantitative species-specific detection and vapA genotyping of Rhodococcus equi.

Authors:  David Rodríguez-Lázaro; Deborah A Lewis; Alain A Ocampo-Sosa; Ursula Fogarty; László Makrai; Jesús Navas; Mariela Scortti; Marta Hernández; José A Vázquez-Boland
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

2.  vanO, a new glycopeptide resistance operon in environmental Rhodococcus equi isolates.

Authors:  Dereje Dadi Gudeta; Arshnee Moodley; Valeria Bortolaia; Luca Guardabassi
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

3.  The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen Rhodococcus equi in mice.

Authors:  Margot Schlusselhuber; Riccardo Torelli; Cecilia Martini; Matthias Leippe; Vincent Cattoir; Roland Leclercq; Claire Laugier; Joachim Grötzinger; Maurizio Sanguinetti; Julien Cauchard
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

4.  Fatal pulmonary infection associated with a novel organism, "para-streptomyces abscessus".

Authors:  W Garrett Nichols; Jennifer Prentice; Yolanda Houze; LaDonna Carlson; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Streptolysin-O/antibiotics adjunct therapy modulates site-specific expression of extracellular matrix and inflammatory genes in lungs of Rhodococcus equi infected foals.

Authors:  Volkan Gurel; Kristyn Lambert; Allen E Page; Alan T Loynachan; Katherine Huges; John F Timoney; Michael Fettinger; David W Horohov; John McMichael
Journal:  Vet Res Commun       Date:  2013-03-09       Impact factor: 2.459

6.  Rapid identification of Rhodococcus equi by a PCR assay targeting the choE gene.

Authors:  Néstor Ladrón; Marta Fernández; Jesús Agüero; Bruno González Zörn; José A Vázquez-Boland; Jesús Navas
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

7.  The LysR-type transcriptional regulator VirR is required for expression of the virulence gene vapA of Rhodococcus equi ATCC 33701.

Authors:  Dean A Russell; Gavin A Byrne; Enda P O'Connell; Clara A Boland; Wim G Meijer
Journal:  J Bacteriol       Date:  2004-09       Impact factor: 3.490

8.  Bacteremia due to Rhodococcus equi: a case report and review of the literature.

Authors:  Xi-yuan Chen; Feng Xu; Jing-yan Xia; Yu-sheng Cheng; Yan Yang
Journal:  J Zhejiang Univ Sci B       Date:  2009-12       Impact factor: 3.066

9.  IcgA is a virulence factor of Rhodococcus equi that modulates intracellular growth.

Authors:  Xiaoguang Wang; Garry B Coulson; Aleksandra A Miranda-Casoluengo; Raúl Miranda-Casoluengo; Mary K Hondalus; Wim G Meijer
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

10.  Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.

Authors:  Jan J Meeuse; Herman G Sprenger; Sander van Assen; Dominique Leduc; Simon M G J Daenen; Jan P Arends; Tjip S van der Werf
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.